Demetri GD et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863):295-302. Abstract

Goodman AM et al. Next generation sequencing reveals potentially actionable alterations in the majority of patients with lymphoid malignancies. JCO Precis Oncol 2017;1:PO.16.00004. Abstract

Heinrich MCC et al. INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib. ASCO Plenary January 2022 Session;Abstract 359881.

Oppelt PJ et al. Gastrointestinal stromal tumors (GISTs): Point mutations matter in management, a review. J Gastrointest Oncol 2017;8(3):466-73. Abstract

Wang Y, Call J. Mutational testing in gastrointestinal stromal tumor. Current Cancer Drug Targets 2019;19(9):688-97. Abstract